University of Illinois at Chicago
Chicago, IL
Accepting patients
MajesTEC-7
A Study to Compare Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
- Has results
Not yet accepting
Personalized Autologous Transplant
Personalized Autologous Transplant for Multiple Myeloma
- Autologous Stem Cell Transplant
- Vaccine
- Phase 1
Not currently accepting
Iberdomide vs. Observation Post Ide-Cel CAR-T
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
- CELMoD
- Maintenance
- Randomization
- Phase 2
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
HEME-18
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- Monoclonal Antibody
- CD38
- Minimal Residual Disease (MRD)
- Maintenance
- Phase 2
Accepting patients
MajesTEC-4
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation - MajesTEC-4
- Bispecific Antibody
- Bispecific T Cell Engager (BiTE)
- BCMA
- Phase 3
Accepting patients
Early Detection Blood Tests
Blinded Reference Set for Multicancer Early Detection Blood Tests
- Observational Trial
1 hidden based on your filters.Show All